Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineActive in the last 2 years

Wei Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2281-8706; OpenAlex author ID A5118969723. Sources: OpenAlex.

Their work

Papers
37 (first author 4, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2020: 1 paper · 2021: 12 papers · 2022: 5 papers · 2023: 11 papers · 2024: 5 papers · 2025: 2 papers · 2026: 1 paper

Papers 37

  1. The CHPT-pSTAT3-SLC7A11 signaling axis controls progression and ferroptosis susceptibility of pancreatic cancer. Co-author DOI 10.1016/j.tranon.2025.102624↗
  2. SMUG1 promoted the progression of pancreatic cancer via AKT signaling pathway through binding with FOXQ1. First author DOI 10.1097/cm9.0000000000003640↗
  3. Dense stroma activates the TGF-β1/FBW7 axis to induce metabolic subtype switching in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000002242↗
  4. Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer. Co-author DOI 10.1007/s12033-023-00875-z↗
  5. Intratumoral CD38+CD19+B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ebiom.2024.105098↗
  6. Deciphering the pancreatic cancer microbiome in Mainland China: Impact of Exiguobacterium/Bacillus ratio on tumor progression and prognostic significance. Last author DOI 10.1016/j.phrs.2024.107197↗
  7. NUSAP1 promotes pancreatic ductal adenocarcinoma progression by drives the epithelial-mesenchymal transition and reduces AMPK phosphorylation. Last author DOI 10.1186/s12885-024-11842-5↗
  8. Identifying the risk factors for pancreatic fistula after laparoscopic pancreaticoduodenectomy in patients with pancreatic cancer. Last author DOI 10.4240/wjgs.v16.i6.1609↗
  9. A new approach: Evaluation of necroptosis and immune status enables prediction of the tumor microenvironment and treatment targets in pancreatic cancer. Co-author DOI 10.1016/j.csbj.2023.03.037↗
  10. Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogeneity of PET-CT. Co-author DOI 10.1016/j.csbj.2023.04.003↗
  11. Intra-tumoral infiltration of adipocyte facilitates the activation of antitumor immune response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2022.101561↗
  12. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Co-author DOI 10.1016/j.xcrm.2023.101234↗
  13. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2022-329349↗
  14. Radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS) for resectable body and tail pancreatic adenocarc… Co-author DOI 10.1186/s13063-023-07456-0↗
  15. Reappraisal of Tumor Deposit as a Prognostic Factor in Pancreatic Cancer. Co-author DOI 10.1245/s10434-023-13102-5↗
  16. Screening of potential pain genes in pancreatic ductal adenocarcinoma (PDAC) based on bioinformatics methods. First author DOI 10.21037/jgo-23-94↗
  17. Cuproptosis-Related Gene DLAT as a Novel Biomarker Correlated with Prognosis, Chemoresistance, and Immune Infiltration in Pancreatic Adenocarcinoma: A Prelimin… First author DOI 10.3390/curroncol30030228↗
  18. Mechanical Regulation of Redox Balance via the Induction of the PIN1/NRF2/ARE Axis in Pancreatic Cancer. Co-author DOI 10.3390/ijms24043476↗
  19. Mesenchymal Stromal Cell-Based Targeted Therapy Pancreatic Cancer: Progress and Challenges. Co-author DOI 10.3390/ijms24043559↗
  20. Turning towards nonimmunoreactive tumors: Evaluation of cancer-associated fibroblasts enables prediction of the immune microenvironment and treatment sensitivi… Co-author DOI 10.1016/j.csbj.2022.07.029↗
  21. The enhanced cell cycle related to the response to adjuvant therapy in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ygeno.2021.11.036↗
  22. Ferroptosis-related lncRNA pairs to predict the clinical outcome and molecular characteristics of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/bib/bbab388↗
  23. Turning up the heat on non-immunoreactive tumors: autophagy influences the immune microenvironment in pancreatic cancer. Co-author DOI 10.1186/s12920-022-01371-0↗
  24. Nomogram for Predicting Distant Metastasis of Pancreatic Ductal Adenocarcinoma: A SEER-Based Population Study. First author DOI 10.3390/curroncol29110643↗
  25. Emerging roles of the solute carrier family in pancreatic cancer. Co-author DOI 10.1002/ctm2.356↗
  26. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00018-021-03866-y↗
  27. Development and multicenter validation of a nomogram for preoperative prediction of lymph node positivity in pancreatic cancer (NeoPangram). Co-author DOI 10.1016/j.hbpd.2020.12.020↗
  28. Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-021-01900-4↗
  29. Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis. Co-author DOI 10.1186/s12943-021-01400-z↗
  30. Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic rev… Co-author DOI 10.21037/gs-21-16↗
  31. Role of LRG1 in the Cell Proliferation, Migration, and Prognosis of Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-733520/v1↗
  32. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.648917↗
  33. Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.643465↗
  34. A Novel Validated Recurrence Stratification System Based on 18F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.650266↗
  35. Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. Co-author DOI 10.3390/ijms222010944↗
  36. Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions. Co-author DOI 10.7150/ijbs.59117↗
  37. Corrigendum: An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness. Co-author DOI 10.3389/fcell.2020.594589↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 29 shared papers, 2021–2026 · strength 4.75
  2. Jie Hua · 27 shared papers, 2021–2026 · strength 4.52
  3. Qingcai Meng · 25 shared papers, 2021–2026 · strength 4.16
  4. Si Shi · 26 shared papers, 2021–2025 · strength 4.08
  5. Jin Xu · 22 shared papers, 2021–2025 · strength 3.65
  6. Chen Liang · 17 shared papers, 2021–2026 · strength 2.65
  7. Bo Zhang · 14 shared papers, 2021–2024 · strength 2.27
  8. Miaoyan Wei · 9 shared papers, 2021–2026 · strength 1.47
  9. Rong Tang · 9 shared papers, 2021–2024 · strength 1.40
  10. Zhen Tan · 6 shared papers, 2021–2026 · strength 1.02
  11. Zeyin Rong · 5 shared papers, 2021–2026 · strength 0.96
  12. Jin Xu · 5 shared papers, 2022–2026 · strength 0.92
  13. Xiaomeng Liu · 5 shared papers, 2021–2023 · strength 0.71
  14. Jianhui Yang · 3 shared papers, 2021–2026 · strength 0.62
  15. Zijian Wu · 3 shared papers, 2021–2025 · strength 0.55
  16. Hang Xu · 2 shared papers, 2023–2024 · strength 0.49
  17. Siyuan Lu · 3 shared papers, 2022–2023 · strength 0.47
  18. Jiang Liu · 3 shared papers, 2021 · strength 0.38
  19. Yuan Liu · 2 shared papers, 2023–2024 · strength 0.38
  20. Qiong Du · 2 shared papers, 2023–2025 · strength 0.37
  21. Zengli Fang · 2 shared papers, 2023 · strength 0.35
  22. Jialin Li · 2 shared papers, 2023 · strength 0.34
  23. Yiyin Zhang · 2 shared papers, 2023 · strength 0.30
  24. Abudureyimu Tuerhong · 2 shared papers, 2021–2023 · strength 0.30
  25. Faliang Xing · 1 shared paper, 2024 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.